The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•24 February 2026•

1 min read

Novo Nordisk's CagriSema Fails to Match Eli Lilly's Zepbound in Weight Loss Trial

Meta and Google logos above social media interfaces, stop signs, legal symbols, and a downward chain with a dollar sign. App logos below.

Key Facts

1Novo Nordisk released late-stage data for its upcoming obesity injection, CagriSema.

2The drug failed to match the weight loss results of Eli Lilly's Zepbound.

Novo Nordisk released highly anticipated late-stage clinical trial data for its next-generation obesity injection, CagriSema. The results indicated that the drug failed to match the weight loss efficacy achieved by Eli Lilly's rival treatment, Zepbound. This development marks a significant setback for the Danish pharmaceutical giant in the increasingly competitive global obesity market. Analysts had expected CagriSema to set a new benchmark, but the trial data suggests it may struggle to gain a competitive edge over existing therapies. Following the announcement, concerns have emerged regarding Novo Nordisk's future market share in the weight-loss sector. Meanwhile, Eli Lilly's position appears strengthened as its flagship drug maintains its lead in clinical performance.